Literature DB >> 25986365

A smaller amygdala is associated with anxiety in Parkinson's disease: a combined FreeSurfer-VBM study.

Chris Vriend1, Premika S W Boedhoe2, Sonja Rutten3, Henk W Berendse4, Ysbrand D van der Werf5, Odile A van den Heuvel2.   

Abstract

BACKGROUND: Up to 50% of all patients with Parkinson's disease (PD) suffer from anxiety symptoms, a much higher percentage than in the general population. This suggests that PD associated pathological alterations partly underlie these symptoms, although empirical evidence is limited.
METHODS: Here we investigated the association between anxiety symptoms measured with the Beck Anxiety Inventory (BAI) and hippocampal and amygdalar volume in 110 early-stage patients with PD. Measures of anxiety in PD are often obscured by overlap with the somatic symptoms. We therefore also used a subscale of the BAI, established by our recent factor analysis, that reflects 'psychological' anxiety symptoms and is independent of the severity of PD-related motor and autonomic symptoms. We used FreeSurfer and voxel-based morphometry for the volumetric analyses.
RESULTS: Both software packages showed a negative correlation between the 'psychological' subscale of the BAI, but not total BAI and volume of the left amygdala, independent of the severity of motor symptoms, autonomic dysfunction and dopaminergic or anxiolytic medication status.
CONCLUSIONS: These results confirm studies in non-PD samples showing lower left amygdalar volume in anxious patients. The results also indicate that the 'psychological' BAI subscale is a better reflection of neural correlates of anxiety in PD. Whether the left amygdalar volume decrease constitutes a premorbid trait, a PD-associated neurobiological susceptibility to anxiety or arises as a consequence of chronic anxiety symptoms remains to be determined by future prospective longitudinal studies. Nonetheless, we speculate that the Parkinson pathology is responsible for the reduction in amygdalar volume and the concomitant development of anxiety symptoms. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  MRI; NEUROBIOLOGY; NEUROPSYCHIATRY; PARKINSON'S DISEASE

Mesh:

Year:  2015        PMID: 25986365     DOI: 10.1136/jnnp-2015-310383

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

Review 1.  Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment.

Authors:  Stephane Thobois; Stephane Prange; Véronique Sgambato-Faure; Léon Tremblay; Emmanuel Broussolle
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-18       Impact factor: 5.081

Review 2.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  Anna Nagy; Anette Schrag
Journal:  J Neural Transm (Vienna)       Date:  2019-05-29       Impact factor: 3.575

Review 3.  Interaction Between Neuropsychiatric Symptoms and Cognitive Performance in Parkinson's Disease: What Do Clinical and Neuroimaging Studies Tell Us?

Authors:  Alexandru Hanganu; Oury Monchi
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-15       Impact factor: 5.081

4.  Distinct neural circuits are associated with subclinical neuropsychiatric symptoms in Parkinson's disease.

Authors:  Sule Tinaz; Serageldin Kamel; Sai S Aravala; Mine Sezgin; Mohamed Elfil; Rajita Sinha
Journal:  J Neurol Sci       Date:  2021-02-21       Impact factor: 3.181

5.  Multi-modal Brain MRI in Subjects with PD and iRBD.

Authors:  Silvia Mangia; Alena Svatkova; Daniele Mascali; Mikko J Nissi; Philip C Burton; Petr Bednarik; Edward J Auerbach; Federico Giove; Lynn E Eberly; Michael J Howell; Igor Nestrasil; Paul J Tuite; Shalom Michaeli
Journal:  Front Neurosci       Date:  2017-12-19       Impact factor: 4.677

Review 6.  Neuropsychiatric symptoms in untreated Parkinson's disease.

Authors:  Szabolcs Szatmari; Ben Min-Woo Illigens; Timo Siepmann; Alexandra Pinter; Annamaria Takats; Daniel Bereczki
Journal:  Neuropsychiatr Dis Treat       Date:  2017-03-16       Impact factor: 2.570

7.  Assessing White Matter Pathology in Early-Stage Parkinson Disease Using Diffusion MRI: A Systematic Review.

Authors:  Maurizio Bergamino; Elizabeth G Keeling; Virendra R Mishra; Ashley M Stokes; Ryan R Walsh
Journal:  Front Neurol       Date:  2020-05-14       Impact factor: 4.003

Review 8.  Depression, anxiety, and apathy in Parkinson's disease: insights from neuroimaging studies.

Authors:  M-C Wen; L L Chan; L C S Tan; E K Tan
Journal:  Eur J Neurol       Date:  2016-06       Impact factor: 6.089

9.  Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease.

Authors:  Satoka Kasai; Toru Yoshihara; Olga Lopatina; Katsuhiko Ishihara; Haruhiro Higashida
Journal:  Front Behav Neurosci       Date:  2017-05-03       Impact factor: 3.558

10.  Late-life falling and depressive symptoms associated with the risk of Parkinson's disease: a nationwide cohort data analysis.

Authors:  Yu Jin Jung; Ryul Kim; Dallah Yoo; Kyungdo Han; Jee-Young Lee
Journal:  BMC Geriatr       Date:  2020-08-10       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.